Relation Between Dabigatran Concentration, as Assessed Using the Direct Thrombin Inhibitor Assay, and Activated Clotting Time/Activated Partial Thromboplastin Time in Patients With Atrial Fibrillation - 28/05/15
, Taishi Kuwahara, MD a, Katsumasa Takagi, MD a, Masateru Takigawa, MD a, Jun Nakajima, MD a, Yuji Watari, MD a, Emiko Nakashima, MD a, Kazuya Yamao, MD a, Tadashi Fujino, MD a, Hiroyuki Tsutsui, MD b, Atsushi Takahashi, MD aAbstract |
Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in patients with atrial fibrillation. In this study, we aimed to assess the associations between the dabigatran concentration (calculated through plasma-diluted thrombin time, as assessed using the Hemoclot assay) and the activated partial thromboplastin time (aPTT) and activated clotting time (ACT). We recruited 137 patients with atrial fibrillation who were receiving a normal dose of dabigatran (300 mg/d) or a reduced dose of dabigatran (220 mg/d, usually administered to patients who were elderly, had moderate renal dysfunction, or who were also receiving verapamil). We then assessed the aPTT, ACT, and Hemoclot results of the patients and calculated the plasma dabigatran concentration. The mean plasma concentration of dabigatran was 127 ± 88 ng/ml, although no significant differences in dabigatran concentration, ACT, or aPTT were observed when we compared the 2 doses of dabigatran (300 or 220 mg/d). The dabigatran concentration was within the therapeutic levels in most patients, although a high value (>300 ng/ml) was observed in several patients, which indicated a high risk of bleeding. The dabigatran concentration was strongly and positively correlated with ACT and aPTT (r = 0.87, p <0.001; and r = 0.76, p <0.001; respectively). Multivariate analysis revealed that verapamil use was independently associated with elevated dabigatran concentrations (p <0.001). Therefore, ACT and aPTT may be useful for bedside assessment of the anticoagulant activity of dabigatran, and verapamil use may be a risk factor for elevated dabigatran concentrations.
Le texte complet de cet article est disponible en PDF.Plan
| See page 1699 for disclosure information. |
Vol 115 - N° 12
P. 1696-1699 - juin 2015 Retour au numéro
Article précédent
- Use of Complementary and Alternative Medicine in Women With Heart Disease, Hypertension and Diabetes (from the Australian Longitudinal Study on Women's Health)
- David Sibbritt, Patricia Davidson, Michelle DiGiacomo, Phillip Newton, Jon Adams
- Ability of Reduced Lung Function to Predict Development of Atrial Fibrillation in Persons Aged 45 to 84 Years (from the Multi-Ethnic Study of Atherosclerosis-Lung Study)
- Harjit Chahal, Susan R. Heckbert, R. Graham Barr, David A. Bluemke, Aditya Jain, Mohammadali Habibi, Alvaro Alonso, Richard Kronmal, David R. Jacobs, Joao A.C. Lima, Karol E. Watson, Kiang Liu, Lewis J. Smith, Philip Greenland
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?